Zeolites in drug delivery : Progress, challenges and opportunities
Copyright © 2020 Elsevier Ltd. All rights reserved..
There are continuing attempts to achieve appropriate controlled-release therapeutic systems by designing innovative functional drug delivery systems (DDS). Although various types of delivery system have been developed, strategies that have successfully made it to the clinic are rare. Given their diverse structures, zeolites have attracted significant research attention for controlled and targeted drug delivery purposes. The structure of zeolites can be microporous, mesoporous or macroporous, which can be exploited to deliver a variety of therapeutic agents to the target site in a controlled manner. In this review, we introduce the different types of zeolite, and discuss the challenges and opportunities associated with their usage as drug delivery systems.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Drug discovery today - 25(2020), 4 vom: 01. Apr., Seite 642-656 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Servatan, Morteza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1318-02-1 |
|---|
| Anmerkungen: |
Date Completed 28.07.2021 Date Revised 28.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drudis.2020.02.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM306561336 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM306561336 | ||
| 003 | DE-627 | ||
| 005 | 20231225123633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2020.02.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1021.xml |
| 035 | |a (DE-627)NLM306561336 | ||
| 035 | |a (NLM)32062009 | ||
| 035 | |a (PII)S1359-6446(20)30073-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Servatan, Morteza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Zeolites in drug delivery |b Progress, challenges and opportunities |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2021 | ||
| 500 | |a Date Revised 28.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a There are continuing attempts to achieve appropriate controlled-release therapeutic systems by designing innovative functional drug delivery systems (DDS). Although various types of delivery system have been developed, strategies that have successfully made it to the clinic are rare. Given their diverse structures, zeolites have attracted significant research attention for controlled and targeted drug delivery purposes. The structure of zeolites can be microporous, mesoporous or macroporous, which can be exploited to deliver a variety of therapeutic agents to the target site in a controlled manner. In this review, we introduce the different types of zeolite, and discuss the challenges and opportunities associated with their usage as drug delivery systems | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Zeolites |2 NLM | |
| 650 | 7 | |a 1318-02-1 |2 NLM | |
| 700 | 1 | |a Zarrintaj, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmodi, Ghader |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Seok-Jhin |e verfasserin |4 aut | |
| 700 | 1 | |a Ganjali, Mohammad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Saeb, Mohammad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Mozafari, Masoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug discovery today |d 1998 |g 25(2020), 4 vom: 01. Apr., Seite 642-656 |w (DE-627)NLM095449159 |x 1878-5832 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2020 |g number:4 |g day:01 |g month:04 |g pages:642-656 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drudis.2020.02.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2020 |e 4 |b 01 |c 04 |h 642-656 | ||